- Market Capitalization, $K 269,445
- Shares Outstanding, K 188,423
- Annual Sales, $ 1,070 K
- Annual Income, $ -27,020 K
- 60-Month Beta 2.51
- Price/Sales 263.37
- Price/Cash Flow N/A
- Price/Book 1.79
|Period||Period Low||Period High||Performance|
| || |
-0.01 (-0.69%)since 09/18/19
| || |
+0.18 (+14.40%)since 07/18/19
| || |
-0.28 (-16.37%)since 10/18/18
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 200,000 shares of Geron common stock as inducements to three newly-hired employees...
Geron enrolls first patient in the late-stage IMerge study to evaluate imetelstat in myelodysplastic syndromes.
Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk...
FinancialBuzz.com News Commentary
In 2019, the American Cancer Society projected 1.76 million new cancer cases diagnosed and the number of deaths to stand at 606,880 in the U.S. Overall, the alarming projection has caused concern within...
Geron's (GERN) sole pipeline candidate, imetelstat, receives Fast Track designation from the FDA for treating relapsed or refractory myelofibrosis. Shares up.
Cancer is the second leading cause of death globally and was responsible for approximately 9.6 million deaths in 2018, according to the World Health Organization (WHO). Statistically, cancer is the cause...
Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to imetelstat for the treatment of adult patients with Intermediate-2...
Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at the 2019 Cantor Global Healthcare Conference...
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late-stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.